Hematologist
CION Cancer Clinics
When adult ALL comes back: the treatment options | CION Cancer Clinics
Relapsed adult ALL can still be treated. Options include a different chemotherapy, antibody medicines such as blinatumomab and inotuzumab, targeted tablets for Philadelphia-positive disease, CAR-T cell therapy and a stem cell transplant. Often the aim is to regain remission, then make it last. This page explains each option, who it does not suit, what the report words mean, and which questions to ask your haematologist. At CION Cancer Clinics, every leukaemia, MDS and MPN case is reviewed by our haematologist and discussed at a tumour board before a plan is agreed.
BP
Medically reviewed by Dr. Basudev PokhrelConsultant Haematologist · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- What can be done if adult ALL comes back?
- What usually happens once relapse is found?
- Which treatments are used for relapsed ALL?
- What is CAR-T, and is it available in India?
- What do the relapse words on the report mean?
- What do families often believe about relapse?
- What can this page not tell you?
- Common questions about relapsed adult ALL
The short answer
What can be done if adult ALL comes back?
There are still real options. Depending on the type of ALL and your fitness, they include more chemotherapy, antibody medicines such as blinatumomab and inotuzumab, targeted tablets for Philadelphia-positive disease, CAR-T cell therapy and a stem cell transplant. Often the aim is to bring back a remission first, then make it last with a transplant or CAR-T.
Why relapse needs a fresh plan
Leukaemia that returns has already survived treatment once, so repeating the same plan rarely works as well. The team usually repeats the bone marrow and genetic tests, because the cells may have changed. The results decide which medicines are likely to act on them.
What matters most in the choice
How long the first remission lasted is one of the biggest factors. So are B-cell or T-cell type, the markers on the leukaemia cells, whether you have already had a transplant, and how well your heart, liver and kidneys are working. Your own wishes matter too. Some people want every option. Others want treatment that keeps them at home more.
Relapse is serious. It is right to ask the team plainly what each option is aiming for.The first weeks
What usually happens once relapse is found?
Confirming the relapse
A bone marrow test, sometimes a lumbar puncture, and tests for markers such as CD19 and CD22 on the leukaemia cells. Genetic tests are often repeated too.
Tumour board review
Haematologists look at the results, your earlier treatment and your fitness together. They agree which options are realistic for you.
Treatment to regain remission
This may be chemotherapy, an antibody medicine, a targeted tablet or a mix. Some people move straight towards CAR-T at a specialist centre.
Planning the next step
If remission returns, the team discusses a transplant or CAR-T to make it last. Donor search for a family member may start early.
Not sure whether this applies to you?
Ask an oncologistThe options
Which treatments are used for relapsed ALL?
Most people receive more than one of these, in sequence. Which ones fit depends on your results and your earlier treatment.
Chemotherapy again
A different combination from the first time. It can work, especially after a long first remission, but is tough on older or frailer adults.
Blinatumomab
An antibody medicine given as a continuous drip. It links your T cells to B-cell leukaemia cells carrying CD19.
Does not suit
- T-cell ALL
- Leukaemia that has lost CD19
Inotuzumab
An antibody that carries a chemotherapy drug directly to cells with CD22. It needs close liver monitoring, particularly if a transplant follows.
Targeted tablets
For Philadelphia-positive ALL, a different tablet may be chosen based on a test for resistance changes in the BCR-ABL1 gene.
Stem cell transplant
Replaces the bone marrow with donor cells after strong treatment. It usually needs a remission first and a suitable donor.
Clinical trials
Newer medicines are tested for relapsed ALL. Ask whether any trial is open that you could join.
CAR-T explained
What is CAR-T, and is it available in India?
CAR-T cell therapy uses your own T cells, a kind of white blood cell. They are collected from your blood, changed in a laboratory to recognise leukaemia cells, and given back through a drip. For B-cell ALL, they usually target CD19.
Where it is done
CAR-T is given at specialist centres, and India now has its own approved CAR-T products as well as imported ones. The process takes weeks, from collecting cells to receiving them. You are then watched closely in hospital, and must stay near the centre for a period afterwards.
Who it does not suit
It is used mainly for B-cell ALL that has come back or not responded. It does not suit T-cell ALL outside trials. People whose leukaemia is growing very fast may not be able to wait for the cells to be made. Serious side effects, such as high fever with falling blood pressure or confusion, need an experienced team.
CION does not give CAR-T in-house. The haematology team reviews your case and coordinates referral to centres that do.Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
On your report
What do the relapse words on the report mean?
- Refractory
- Leukaemia that did not go into remission with treatment, as opposed to coming back after one.
- Early or late relapse
- Whether the leukaemia returned soon after treatment or long after. Late relapse often responds better.
- CD19 and CD22
- Markers on the surface of B-cell leukaemia cells. Antibody medicines and CAR-T target them.
- Isolated CNS relapse
- Leukaemia found only in the fluid around the brain and spine, not in the bone marrow.
- Salvage treatment
- Treatment given after relapse to bring back a remission.
Commonly believed
What do families often believe about relapse?
"Relapse means the first hospital did something wrong."
ALL can come back even after excellent treatment, because a few cells can survive every test. Moving hospitals out of blame can delay care. If you want a second opinion, ask for one while treatment continues.
"CAR-T is the answer for everyone who relapses."
CAR-T is an important option for B-cell ALL. It does not suit everyone, it takes weeks to prepare, and the leukaemia can still return afterwards. Many people need other treatment before or after it.
"There is nothing left once a transplant has been done."
Relapse after transplant is hard, but options may still exist, including antibody medicines, CAR-T, trials or adjusting the donor immune effect. Ask the transplant team what is realistic.
"Choosing comfort care means giving up."
Palliative care, which focuses on symptoms and quality of life, can run alongside active treatment. Choosing it later is a valid decision, not a failure.
Being straight with you
What can this page not tell you?
It cannot tell you which option will work for you, or how likely any option is to succeed. Those answers come from your own marrow results, markers, earlier treatment and fitness, read by your haematologist.
Questions worth asking
What is the aim of this treatment: remission, a bridge to transplant or CAR-T, or more time with good quality of life? What are the main risks for someone like me? How long will I be in hospital? Is there a trial I could join? What happens if this does not work? Writing these down before the appointment helps, especially if several family members want to ask.
Cost and access
Antibody medicines, CAR-T and transplant can be expensive, and access varies between centres. Ask early about Aarogyasri, PM-JAY, CGHS, ECHS, EHS or insurance cover, and about patient support programmes. Scheme rules change, so check what applies now.
Questions we are asked
Common questions about relapsed adult ALL
How do doctors know the leukaemia has come back?
Sometimes a routine blood count shows leukaemia cells or falling counts. Sometimes a follow-up MRD test finds hidden disease rising first. A bone marrow test confirms it. Symptoms such as tiredness, bruising, fevers or bone pain should always be reported quickly, even between visits.
Is CAR-T better than a transplant?
They are different, and are often used together or one after the other. CAR-T can bring back remission in B-cell ALL. A transplant may then be used to make it last. Which comes first depends on your marrow results, donor availability and earlier treatment. Your team will explain the order they suggest.
Can blinatumomab be given without a long hospital stay?
It is given as a continuous drip through a small pump. The start of each course usually needs hospital monitoring. Some centres then allow part of it at home with a portable pump and frequent visits. Ask the team what arrangement is safe for you.
My mother relapsed and she is older. Is treatment still worth it?
That depends on her fitness, her wishes and the type of ALL. Antibody medicines may suit some older adults better than intensive chemotherapy. Ask the team what each option aims for, what it would mean for her daily life, and whether comfort-focused care should run alongside.
Does CION provide CAR-T or transplant?
CION's haematology team evaluates the case, presents it at a tumour board and coordinates referral to qualified transplant and CAR-T centres. Ask each centre about waiting time, where you must stay afterwards, and what the estimate includes.
Will family members need to be tested as donors?
If a transplant is likely, brothers and sisters are often tested first, because they are most likely to match. Parents and children can sometimes be half-matched donors. Unrelated registry donors are another route. Ask the transplant centre early, because the search can take time.
Can relapse be prevented by lifestyle changes?
No lifestyle change is known to prevent ALL coming back. Taking maintenance medicines as planned, attending follow-up tests and reporting symptoms early are what help. Eating well and staying active help you cope with treatment if relapse does happen.
Should we get a second opinion after relapse?
A second opinion is reasonable, especially before CAR-T or a transplant. Bring every report, including earlier marrow, genetic and MRD results. Try not to pause treatment while waiting, and tell your current team, so the opinions can be joined up.
Your Haematologist
Meet CION's haematologist. One specialist for your blood report and your plan.
Dr. Basudev Pokhrel reviews blood counts, transfusion needs and blood disorders, and works with the CION tumour board on blood cancers.
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- National Cancer Institute — Adult Acute Lymphoblastic Leukemia Treatment (PDQ) - Patient Version
- National Cancer Institute — CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers
- Cancer Research UK — Acute lymphoblastic leukaemia (ALL)
- Leukemia & Lymphoma Society — Acute Lymphoblastic Leukemia (ALL)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Blinatumomab and Inotuzumab in Adult ALLThe two antibody medicines in more detailWhen Adult ALL Needs a TransplantHow the transplant decision is madeMRD-Guided Treatment in Adult ALLHow hidden disease is trackedImmunotherapy guideHow immune-based treatments workAcute Lymphoblastic Leukaemia in AdultsThe full adult ALL guide
Talk to us
Facing a relapse and need a plan?
Share the latest marrow and genetic reports. CION's haematology team will review the options with you and coordinate referral where needed. One helpline serves every CION centre.